Lixte Biotechnology Holdings (FRA:8640) Research & Development : €0.64 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Lixte Biotechnology Holdings's Research & Development for the three months ended in Mar. 2025 was €0.08 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €0.64 Mil.

Lixte Biotechnology Holdings Research & Development Historical Data

The historical data trend for Lixte Biotechnology Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Research & Development Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

1.01

1.54

1.27

0.82

0.69

Lixte Biotechnology Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Research & Development	Get a 7-Day Free Trial															0.11	0.20	0.33	0.03	0.08

Lixte Biotechnology Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.64 Mil.

Lixte Biotechnology Holdings (FRA:8640) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lixte Biotechnology Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Lixte Biotechnology Holdings Headlines

No Headlines